Lantern Pharma Advances Pediatric Cancer Trial with FDA Guidance on AI-Driven Therapy
September 3, 2025 — Lantern Pharma receives FDA guidance for pediatric CNS cancer trial using AI-driven therapy LP-184/STAR-001. Trial targets ATRT with Rare Pediatric Disease designation.